Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (273)
Related Products (273)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
TQ-3959
0 ImagesCat. No.: HY-175541CAS No.: 2926610-43-5
-
JAK3/BTK-IN-5
0 ImagesCat. No.: HY-143720CAS No.: 2673196-75-1JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, example 35)
-
BTK-IN-48
0 ImagesCat. No.: HY-182293CAS No.: 3114078-55-3
-
BTK-IN-43
0 ImagesCat. No.: HY-172589CAS No.: 3081685-04-0BTK-IN-43 (compound 9) is an inhibitor of BTK with an IC50 value of 21.6 nM. BTK-IN-43 has oral activity.
-
BTK ligand-17
0 ImagesCat. No.: HY-175788BTK ligand-17 (The Target Protein Ligand Moiety of Catadegbrutinib) is a BTK ligand. BTK can be used as Ligands for Target Protein for PROTAC to develop and design degradative agents for PROTAC BTKs, such as Catadegbrutinib (HY-160141). BTK ligand-17 can also be used in cancer research.
-
HZ-A-005
0 ImagesCat. No.: HY-147784CAS No.: 2041789-14-2HZ-A-005 is a potent, selective, and covalent Bruton’s tyrosine kinase (BTK) inhibitor. HZ-A-005 markedly decreases tumor growth in xenograft mouse models.
-
BTK-IN-6
0 ImagesCat. No.: HY-142932BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8).
-
Faldoritinib
0 ImagesCat. No.: HY-187867CAS No.: 2910764-59-7Faldoritinib is a Tyrosine kinase inhibitor and antineoplastic agent.
-
BTK ligand 1
0 ImagesCat. No.: HY-150885CAS No.: 330785-90-5BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies.
-
BTK inhibitor 20
0 ImagesCat. No.: HY-143730CAS No.: 2696450-27-6
-
JAK3/BTK-IN-6
0 ImagesCat. No.: HY-147754CAS No.: 2243136-03-8
